

Key Guardant Health and collaborator presentations at AACR 2026

Presentation	Title	Time / Location
	<i>Monday, April 19</i>	
1316	A methylation-based molecular tumor typing classifier for tissue samples from cancers of unknown primary	April 19, 2026 / 3:00 PM - 5:00 PM PT
	<i>Tuesday, April 20</i>	
4016	Tissue-based homologous recombination deficiency status prediction in patients with breast, ovarian, and pancreatic cancers	April 20, 2026 / 2:30 PM - 4:30 PM PT
2279	DNA methylation-based classifier predicts SERD benefit in <i>ESR1</i> wild-type HR+/HER2- breast cancer	April 20, 2026 / 9:00 AM - 12:00 PM PT Poster hall / Section 34
	<i>Wednesday, April 21</i>	
6512	Exploring clinical actionability of expanded liquid biopsy in advanced breast and colorectal cancers	April 21, 2026 / 2:00 PM - 5:00 PM PT Poster Section 43
6512	Evaluating molecular tumor type predictions for identifying new primary malignancies - A real-world clinical genomics analysis	April 21, 2026 / 2:00 PM - 5:00 PM PT Poster Section 43
CT230	STRIDE regimen of tremelimumab and durvalumab as non-operative management strategy of MSI-H resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC): final results of the cohort 2 of INFINITY study by GONO GI	April 21, 2026 / 10:15 AM – 12:15 PM PT

The full abstracts for Guardant Health and a list of all abstracts being presented at the AACR Annual Meeting can be found [here](#).